A Phase I trial of combined azactidine and lenalidomide salvage therapy in patients with acute myeloid leukaemia who relapse after allogeneic stem cell transplantation

Trial Profile

A Phase I trial of combined azactidine and lenalidomide salvage therapy in patients with acute myeloid leukaemia who relapse after allogeneic stem cell transplantation

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms VIOLA
  • Most Recent Events

    • 02 Feb 2017 Status changed from recruiting to completed.
    • 09 Dec 2015 Accrual to date is 53% according to United Kingdom Clinical Research Network record.
    • 05 Oct 2015 Accrual to date is 50% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top